药明生物与Sinorda Biomedicine达成战略合作 加速创新双特异性抗体开发与生产

美股速递
Jan 29

药明生物与Sinorda Biomedicine宣布建立战略合作伙伴关系,双方将共同推进一款创新双特异性抗体的开发及生产进程。此次合作旨在整合药明生物领先的抗体药物研发平台与Sinorda Biomedicine的创新技术,加速该创新疗法的产业化进程。

通过优势资源互补,合作双方将聚焦双特异性抗体药物的工艺开发、质量控制及规模化生产等关键环节。这种协同创新模式有望为全球患者带来更高效的治疗方案,同时推动生物医药行业的技术进步。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10